Daxor

Daxor Forward P/E

The Forward P/E Ratio of Daxor (DXR) as of Oct 19, 2026 is 7.30. In the previous year, Forward P/E Ratio was 124.74 — a change of -94.15% (lower).

Forward P/E

7.30

YoY

-94.15%

Last updated:

Forward P/E Ratio of Daxor is 2025 7.30 . Forward P/E Ratio of Daxor was 2024 124.74 . It decreases by -94.15% lower compared to the previous year.

The Daxor Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-75.53 USD
Jan 1, 2019
-134.96 USD
Jan 1, 2020
-39.23 USD
Jan 1, 2021
14.09 USD
Jan 1, 2022
12.92 USD
Jan 1, 2023
238.38 USD
Jan 1, 2024
124.74 USD
Jan 1, 2025
7.30 USD
The Daxor Forward P/E history
YEARForward P/EYoY
7.30-94.15%
124.74-47.67%
238.38+1,745.12%
12.92-8.30%
14.09-135.92%
-39.23-70.93%
-134.96+78.69%
-75.53+39.98%
-53.96-217.41%
45.96-728.29%
-7.31-89.32%
-68.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Daxor Stock analysis

What does Daxor do? Daxor Corp, listed on the ticker DXR with ISIN US2394671034, is a health care company based in New York City, United States. The company went public on July 25, 1983. Daxor Corp develops and manufactures the BVA-100 blood volume analyzer, a diagnostic instrument cleared by the U.S. Food and Drug Administration (FDA). This device measures human blood volume and provides objective quantification of blood volume status and composition relative to patient-specific norms. The company reports that over 65,000 tests have been conducted at hospital centers across the United States. These tests are associated with improvements in hospital performance metrics for various surgical and medical conditions, including reductions in mortality and readmissions for heart failure and critical care patients. Daxor Corp is engaged in advancing healthcare through blood volume analysis, focusing on optimal fluid management. The company is conducting ongoing clinical trials related to heart failure treatment, supported by the National Institutes of Health (NIH), and is also under contract to develop additional analyzers. The company's website is https://www.daxor.com/. Daxor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Daxor stock

Forward P/E Ratio of Daxor is 7.30 in 2025.

Forward P/E Ratio of Daxor changed from 124.74 to 7.30, representing a -94.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Daxor since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Daxor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Daxor

All Key Metrics — Daxor